Skip to ContentSkip to Navigation
breed in kennis  -  sterk in techniek
Over ons Praktische zaken Waar vindt u ons dr. ir. A.M.G. Pasmooij

Publicaties

More Than a Question of Correlation: Characterization of the Evidentiary Basis for Biomarker Surrogates Used in European Marketing Authorizations

Repurposing Candidate Drugs to Prevent SARS-CoV-2: A PharmLines Test-Negative Case–Control Study

Biomarkers for neurodegenerative diseases in regulatory decision-making by the European Medicines Agency

Core outcome domain sets for clinical trials in epidermolysis bullosa — a COSEB protocol to achieve consensus on “what” to measure

Effectiveness of COVID-19 vaccines against SARS-CoV-2 infection and severe outcomes in adults: A systematic review and meta-analysis of European studies published up to 22 January 2024

Insights from the European Medicines Agency on digital health technology derived endpoints

Learning from European regulator-initiated studies for regulatory decision making

Protocol for the Development of a Core Outcome Set for Inherited Ichthyosis

Harmonization of outcomes in epidermolysis bullosa: report of the Core Outcome Sets for Epidermolysis Bullosa (COSEB) kick-off meeting

Patients suffering from dystrophic epidermolysis bullosa are prone to developing autoantibodies against skin proteins: A longitudinal confirmational study

Sustainable Development Goals

SDG 3 – Goede gezondheid en welzijn

Meer informatie over de Sustainable Development Goals.